Inhibition of Poly(ADP-ribose)polymerase impairs Epstein Barr Virus lytic cycle progression
2007

How a Drug Affects the Epstein-Barr Virus Cycle

publication Evidence: moderate

Author Information

Author(s): Mattiussi Stefania, Tempera Italo, Matusali Giulia, Mearini Giulia, Lenti Luisa, Fratarcangeli Silvia, Mosca Luciana, D'Erme Maria, Mattia Elena

Primary Institution: University 'Sapienza'

Hypothesis

Does inhibiting PARP-1 affect the lytic cycle of Epstein-Barr Virus?

Conclusion

Inhibiting PARP-1 impairs the progression of the Epstein-Barr Virus lytic cycle and reduces viral particle release.

Supporting Evidence

  • Inhibition of PARP-1 reduced cell damage and apoptosis in Raji cells.
  • 3-ABA treatment increased levels of latent viral proteins LMP1 and EBNA2.
  • Viral DNA release was significantly lower in the presence of 3-ABA.

Takeaway

The study shows that a drug can help stop the Epstein-Barr Virus from spreading by affecting how it grows.

Methodology

The study involved treating Burkitt lymphoma-derived Raji and Jijoye cells with a PARP-1 inhibitor and analyzing the effects on EBV lytic cycle activation.

Digital Object Identifier (DOI)

10.1186/1750-9378-2-18

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication